We’re tracking in-house compensation. Take the Law360 Survey
Click here
Ayoub, et al v. Spectrum Pharmaceuticals, Inc. et al
-
June 23, 2026
A New York federal judge preliminarily approved a $7 million deal resolving class action claims alleging Spectrum Pharmaceuticals Inc. overstated its regulatory prospects for winning approval for a cancer treatment.
-
June 02, 2026
A Spectrum Pharmaceuticals Inc. investor has asked a New York federal court to approve a $7 million deal resolving class action claims alleging the drugmaker overstated its regulatory prospects for winning approval for a cancer treatment.
-
January 07, 2026
Kaplan Fox & Kilsheimer LLP will continue leading a putative securities class action against Spectrum Pharmaceuticals after a previously appointed lead plaintiff was removed from the case for allegedly going behind his lawyers' backs to push his own settlement plan and unrelated conspiracy theories.
-
August 05, 2025
The lead plaintiff in a securities class action against Spectrum Pharmaceuticals in Manhattan federal court was removed from the case Tuesday when a federal judge found he broke confidentiality rules by going behind his lawyers' backs in an attempt to push his own settlement plan and fixating on unrelated conspiracy theories.
-
January 23, 2024
Spectrum Pharmaceuticals must face a consolidated proposed securities class action alleging it misled investors about a lung cancer treatment drug study after a New York federal judge decided Tuesday that the suit adequately alleged the defendants "consciously or recklessly" made false or misleading statements.